---
title: "Unicycive Therapeutics, Inc. Stock 12‑Month Price Target Cut to $32.7, Implies 554% Upside"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/295694317.md"
description: "Unicycive Therapeutics' average 12-month price target was lowered from $37.5 to $32.7 by 10 analysts, with forecasts ranging between $13 and $61. Despite the cut, the consensus rating remains 'Buy'. Based on the August 11 closing price, this new target implies a potential upside of approximately 554%."
datetime: "2026-08-12T17:20:09.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/295694317.md)
  - [en](https://longbridge.com/en/news/295694317.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/295694317.md)
generator: "portal-rs"
---

# Unicycive Therapeutics, Inc. Stock 12‑Month Price Target Cut to $32.7, Implies 554% Upside

-   According to estimates from 10 analysts, Unicycive Therapeutics, Inc. stock's average price target has fallen from $37.5 to $32.7, with forecasts ranging from $13 to $61 per share
-   Based on the Aug. 11 closing price, the updated target implies approximately 554% potential upside
-   Consensus rating remains at “Buy” across 10 covering analysts, with 10 Buys, 0 Holds and 0 Sells

Explore more price target data and ratings for Unicycive Therapeutics, Inc. on the , and track all previous and future analyst recommendations for Unicycive Therapeutics, Inc. in the dedicated News Flow.

**Disclaimer**

Select reference data provided by FactSet. Copyright © 2026 FactSet Research Systems Inc. This information is not a recommendation for what you should do personally and does not constitute investment advice.

### Related Stocks

- [UNCY.US](https://longbridge.com/en/quote/UNCY.US.md)
- [FDS.US](https://longbridge.com/en/quote/FDS.US.md)

## Related News & Research

- [Analyst Reaffirms Buy Rating on Unicycive, Maintaining 12-Month Price Target at $30 After FDA Procedural Setback](https://longbridge.com/en/news/296255704.md)
- [Unicycive Therapeutics posts corporate presentation on kidney disease drug pipeline, led by OLC for dialysis hyperphosphatemia](https://longbridge.com/en/news/296044732.md)
- [Citizens Jmp Reaffirms "Market Outperform" Rating for Allogene Therapeutics (NASDAQ:ALLO)](https://longbridge.com/en/news/296112335.md)
- [Unicycive Therapeutics Announces Second Quarter 2026 Financial Results and Provides Business Update](https://longbridge.com/en/news/295797130.md)
- [Unicycive says FDA issues CRL for OLC NDA over third-party manufacturing deficiencies](https://longbridge.com/en/news/291271373.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**